Acurx Pharmaceuticals, Inc.'s SEC filings document a late-stage biopharmaceutical issuer developing antibiotics for difficult-to-treat Gram-positive bacterial infections. Registration statements describe securities offerings, resale registration mechanics, common stock, warrants and the company's status as an emerging growth company and smaller reporting company.
ACXP's Form 8-K filings record material events tied to capital structure, governance and compensation, including amendments to authorized common shares and executive and director compensation arrangements. The filings also cover Nasdaq-listed common stock, operating and financial results, material agreements, shareholder voting matters and risk disclosures associated with antibiotic research and development.
Acurx Pharmaceuticals, Inc. (ACXP) amended its bylaws effective October 29, 2026, lowering the quorum for stockholder meetings to one-third (33⅓%) of the voting power of stock outstanding and entitled to vote. The threshold counts voting power present in person, by remote communication if applicable, or represented by proxy.
The new threshold applies except where a higher quorum is required by law, the certificate of incorporation, or the bylaws. Previously, a majority of shares entitled to vote, present in person or by proxy, constituted a quorum unless law required a larger number.
Acurx Pharmaceuticals, Inc. (ACXP) shareholders elected David P. Luci and Jack H. Dean as Class II directors for three-year terms expiring in 2029, and ratified CohnReznick LLP as independent registered public accounting firm for fiscal 2026. Luci received 1,187,323 votes for and 73,804 withheld; Dean received 1,203,310 votes for and 57,817 withheld. Each nominee had 1,629,772 broker non-votes. The accounting firm appointment received 2,877,193 votes for, 8,473 against and 5,233 abstentions. As of August 20, 2026, 5,471,297 common shares were outstanding and entitled to vote. Holders of 2,890,899 shares were represented at the October 16, 2026 annual meeting, constituting a quorum.
Acurx Pharmaceuticals, Inc. (ACXP) is registering up to 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. Acurx is not selling shares directly in this offering and will not receive proceeds from Lincoln Park’s resales. Separately from this resale, Acurx may still sell additional shares to Lincoln Park under the Purchase Agreement and receive up to $2.8 million in remaining aggregate gross proceeds, which it plans to use for working capital and general corporate purposes. The Lincoln Park facility totals $12.0 million, of which $9.2 million has already been raised through prior registered share sales. Common shares outstanding were 5,559,405 as of August 31, 2026, and would be 7,059,405 if all 1,500,000 registered shares are issued and sold to Lincoln Park.
Acurx Pharmaceuticals, Inc. (ACXP) filed a Form S-1 to register 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares may be issued to Lincoln Park at Acurx’s discretion over a 24‑month term.
Acurx is a late-stage biopharmaceutical company developing Gram‑positive–targeted antibiotics, including candidates for Clostridioides difficile and other priority pathogens. The company has already sold $9.2 million of stock to Lincoln Park and may sell up to an additional $2.8 million, with proceeds intended for working capital, research and development, and general corporate purposes. Existing holders face potential dilution, and Lincoln Park is deemed an underwriter for these resale shares.
Acurx Pharmaceuticals, Inc. (ACXP) is soliciting proxies for its 2026 virtual annual meeting to be held at 10:00 a.m. EST on October 16, 2026. Stockholders of record as of August 20, 2026, when 5,471,297 common shares were outstanding, may vote online, by phone, mail, or during the webcast.
Stockholders are asked to elect two Class II directors, David P. Luci and Jack H. Dean, to three‑year terms ending in 2029, and to ratify CohnReznick LLP as independent registered public accounting firm for 2026. The board recommends voting FOR both proposals. The board remains classified into three classes and includes a majority of Nasdaq‑defined independent directors.
The filing details beneficial ownership, with all directors and current executive officers as a group holding 350,608 shares (6.5%) as of August 15, 2026. It also presents 2025 executive compensation, including base salaries, cash and non‑cash bonuses, and stock option grants (some in lieu of cash bonuses), along with director retainers and committee fees and the status of the 2021 Equity Incentive Plan.
Acurx Pharmaceuticals is a clinical-stage biotech focused on novel DNA polymerase IIIC inhibitors, led by ibezapolstat for C. difficile infection. The company reported no revenue for the quarter and continues to operate at a loss while advancing its pipeline, including a new open-label pilot trial in recurrent CDI to inform planned Phase 3 development.
For the six months ended June 30, 2026, operating expenses were $4.0 million, down 10% from 2025, as a 21% decline in general and administrative costs offset higher research and development spending of $1.4 million. Net loss narrowed to $3.9 million from $4.4 million, and operating cash outflow was $3.1 million. Liquidity improved through equity financings: an April 2026 registered direct offering and ongoing sales under a $12.0 million equity line generated $6.2 million of cash in the first half, lifting cash to $10.7 million and shareholders’ equity to $8.2 million.
Management states that current cash is not sufficient to meet anticipated needs for at least 12 months from issuance of these financial statements and plans to seek additional equity and grant funding. The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern. Acurx remains listed on Nasdaq following an earlier reverse stock split, while new Nasdaq market value requirements are currently stayed by the SEC.
Acurx Pharmaceuticals is registering up to 1,300,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC. These are Purchase Shares reserved under a Purchase Agreement dated May 8, 2025 and covered by a registration rights agreement. The company will not receive proceeds from resales by Lincoln Park under this prospectus; however, Acurx may sell additional shares to Lincoln Park under the Purchase Agreement for up to $4.7 million in aggregate gross proceeds remaining available to the company, subject to the Purchase Agreement terms, the Beneficial Ownership Cap, and our decision to direct purchases.
The registration covers shares that are freely tradable when issued and may be resold in various methods described in the Plan of Distribution. The arrangement follows prior registrations that have already resulted in $7.3 million of gross proceeds to Acurx from Lincoln Park purchases.
Acurx Pharmaceuticals, Inc. is registering 1,650,170 shares of common stock issuable upon exercise of series H warrants.
The prospectus states the warrants have an exercise price of $2.78 per share, are immediately exercisable and expire twenty-four months following the effective date of the registration statement. The selling stockholders will receive all sale proceeds; the company will receive proceeds only to the extent the warrants are exercised for cash.